[Specificities of neonatal hemostasis and implications in pathologic situations].
The haemostasis of healthy newborn differs from those of normal adult but remains well balanced without bleeding or thrombosis. However, this equilibrium is unstable, and the neonate is exposed to acquired or inherited haemostasis disorders that necessitate to be early diagnosed in order to be appropriately treated. Several studies provided reference ranges for haemostatic components in the foetus, the newborn and throughout childhood. The particularities of neonatal haemostasis are therefore better defined and contribute to further understand the pathophysiology and characteristics of hemorrhagic and thrombotic disorders that occur in newborns. Some examples of the impact of age on haemostasis are: the risk of neonatal alloimmune thrombocytopenia is high in the first newborn of a woman at risk since the involved antigens are fully expressed by foetal platelets; the newborn is at risk for vitamin K deficiency with bleeding due to poor transport of vitamin K across the placenta and low levels of coagulation factors II, VII, IX, X; the diagnosis of some inherited coagulation deficiencies can be difficult in the newborn due to physiologically low levels of coagulation factors; thrombotic events are rare in the healthy neonate, despite physiologically very low levels of several coagulation inhibitors; the pharmacokinetic and effects of antithrombotic agents are influenced by the specificities of haemostasis in neonates. This review will discuss about the foetal development of haemostasis until birth, and some implications regarding the pathophysiology, the diagnosis and the treatment of bleeding disorders in the human neonate.
Gruel
Y
Y
Service d'Hématologie-Hémostase, Hôpital Trousseau, 37044 Tours cedex 9, France. gruel@med.univ-tours.fr
D000328:Adult; D005168:Factor VII Deficiency / Q000175:diagnosis / Q000235:genetics; D005171:Factor X Deficiency / Q000175:diagnosis / Q000235:genetics; D005260:Female; D047109:Fetal Development; D005315:Fetal Diseases / Q000145:classification; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D002836:Hemophilia B / Q000175:diagnosis / Q000235:genetics; D006487:Hemostasis / Q000502:physiology*; D020141:Hemostatic Disorders / Q000145:classification* / Q000188:drug therapy; D006801:Humans; D007020:Hypoprothrombinemias / Q000175:diagnosis / Q000235:genetics; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000145:classification* / Q000188:drug therapy; D008297:Male; D010920:Placenta / Q000502:physiology; D011247:Pregnancy
D005343:Fibrinolytic Agents